Compare KD & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | RYTM |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.4B |
| IPO Year | N/A | 2017 |
| Metric | KD | RYTM |
|---|---|---|
| Price | $25.38 | $102.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $39.60 | ★ $128.54 |
| AVG Volume (30 Days) | ★ 2.0M | 658.3K |
| Earning Date | 02-02-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $15,008,000,000.00 | $174,334,000.00 |
| Revenue This Year | $6.40 | $47.34 |
| Revenue Next Year | $3.60 | $55.95 |
| P/E Ratio | $15.01 | ★ N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $23.28 | $45.91 |
| 52 Week High | $44.20 | $122.20 |
| Indicator | KD | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 37.31 | 45.21 |
| Support Level | $26.79 | $96.20 |
| Resistance Level | $27.68 | $114.00 |
| Average True Range (ATR) | 0.84 | 5.41 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 2.47 | 33.31 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.